Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
3(23%)
Results Posted
56%(5 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
7
54%
Ph phase_1
1
8%
Ph phase_2
4
31%
Ph phase_4
1
8%

Phase Distribution

1

Early Stage

4

Mid Stage

8

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
4(30.8%)
Phase 3Large-scale testing
7(53.8%)
Phase 4Post-market surveillance
1(7.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.0%

9 of 10 finished

Non-Completion Rate

10.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(9)
Terminated(1)

Detailed Status

Completed9
Recruiting2
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 24 (30.8%)
Phase 37 (53.8%)
Phase 41 (7.7%)

Trials by Status

active_not_recruiting18%
terminated18%
completed969%
recruiting215%

Recent Activity

Clinical Trials (13)

Showing 13 of 13 trials
NCT04766723Phase 2

A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm

Completed
NCT03992404Phase 3

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury

Active Not Recruiting
NCT07122193Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Recruiting
NCT07210463Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Recruiting
NCT05773053Phase 2

A Study of NT 201 Doses in the Treatment of Platysma Prominence

Completed
NCT05784363Phase 1

A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face

Completed
NCT04622254Phase 3

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines

Completed
NCT04594213Phase 3

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines

Completed
NCT03806933Phase 2

Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines

Completed
NCT02270736Phase 3

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability

Completed
NCT00541905Phase 4

Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia

Completed
NCT00694148Phase 3

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Completed
NCT00507637Phase 2

Blepharospasm Short Interval

Terminated

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13